News Articles
Emmes Group recognized as a top EDC platform by Everest Group
×
Press Release
Emmes Group named a ‘Major Contender’ in the Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix® Assessment 2024 from Everest
Emmes Group, a global contract research and technology organization, has been recognized in the Everest Group’s recently published ‘Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix® Assessment 2024’ for its Advantage eClinical Cloud EDC platform. Advantage eClinical Cloud, is a unified eClinical platform combining technology, data, analytical and AI capabilities to modernize and accelerate clinical research. This is the first time Emmes Group has been included in a Peak Matrix® Assessment.
Sastry Chilukuri, CEO of Emmes Group, commented, “We’re honored to be recognized as a major contender by Everest Group. This award is recognition not only of Advantage eClinical Cloud’s capabilities, but also the impact it’s had with our customers. We’re excited for the future of the platform, as we continue to build out capabilities with embedded AI.”
In the first ever EDC edition, the PEAK Matrix® Assessment evaluated 20 platform providers based on market impact, as well as vision & capability. Assessment criteria included technology capabilities, flexibility and ease of deployment, engagement, and training support, as well as market adoption and portfolio mix. Advantage eClinical Cloud distinguished itself through its unified platform, streamlined configuration and industry leading AI capabilities. The assessment also noted Emmes therapeutic area and domain expertise within clinical research.
Nisarg Shah, Practice Director at Everest Group, said, "Emmes Group provides a unified eClinical solution combining EDC with eCOA/ePRO, RTSM, specimen, and lab data. It features therapeutic area-specific libraries, low-code configuration, AI-based edit checks, and CDASH harmonization. Emmes Group is recognized for its cost-effectiveness and deep experience in clinical research, as well as its global operations expertise. These strengths, advanced features, and domain expertise have positioned Emmes Group as a Major Contender in the EDC PEAK Matrix® Assessment 2024."
Rama Kondru, CEO of Veridix AI, added “At the forefront of clinical technology, our unified platform is redefining the EDC segment. With a modern technology stack that eliminates cumbersome ETLs, and a CDASH unified data model, we’re streamlining data transformations. While our embedded AI and interactive reporting are shortening timelines and accelerating insights. This empowers our clients to make data-driven decisions with unprecedented speed and accuracy, from study start up to regulatory filing."
Advantage eClinical Cloud has powered more than 1,200 clinical trials with over 1.1 million patients across multiple therapeutic areas, countries, languages, and clinical trial phases. With adoption and use by more than 32,000 sites and 58,000 users, Advantage eClinical Cloud provides users with a unified, easy-to-use platform for clinical research across sponsors, sites, and patients.
About Emmes Group:
Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (https://www.newmountaincapital.com). The company is transforming the future of clinical research, bringing the promise of new medical discovery closer within reach for patients. Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Today, the company is transforming the future of clinical research, by creating the industry’s first specialty, tech and AI based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence. Learn more at www.theemmesgroup.com.
About Veridix AI:
Veridix AI is the technology and AI division of Emmes Group, dedicated to pioneering advancements in AI and patient-centric technologies. We are passionate about serving patients by bringing the latest technological and analytical advancements to clinical research. Through constant innovation we aim to increase the pace of clinical trials and help bring new treatments to patients more quickly. Combining our expertise with Emmes CRO’s operational and scientific excellence, we are modernizing clinical research. Learn more at www.veridixai.com.
For media enquiries, please contact:
Dana Roche
Director, Marketing and Communications
droche@emmes.com
Press Release
Emmes Group partners with Miimansa AI to accelerate adoption of Generative AI in clinical research
Emmes Group partners with Miimansa AI to accelerate adoption of Generative AI in clinical research
×
Press Release
July 23, 2024 – Rockville, MD – Emmes Group, a leading specialty tech-enabled global contract research organization (CRO), today announced a multi-year strategic partnership with Miimansa AI. A critical pillar of the partnership, aimed at revolutionizing clinical research at Emmes, is the acquisition of Miimansa’s Clinical Entity Modeling tools based on advanced large language modeling (LLM) techniques and generative AI.
Artificial intelligence (AI) promises to transform all aspects of healthcare including clinical research. Emmes Group is rapidly maturing its technology platform, Veridix AI, and Miimansa’s Clinical Entity Modeling technology will serve as a critical building block to accelerate the development of state-of-the-art automated text processing solutions tailored for clinical research.
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data and enabling text to text transformations such as protocol authoring and medical writing, reducing the time and cost associated with manual data handling and analysis.
"We are excited to partner with Miimansa AI to bring cutting-edge AI technology to the forefront of clinical research," said Sastry Chilukuri, CEO of Emmes Group. “The clinical entity modeling tools acquired through our partnership will accelerate development and adoption of Emmes Groups’ Gen AI platform, named Concord, to drive faster, better and more efficient clinical trials.”
Dr. Vibhu Agarwal, founder and CEO of Miimansa AI, added, "Teaming up with Emmes Group is a significant milestone for us. Their expertise and comprehensive clinical trial data offer a unique opportunity to apply our advanced AI techniques in real-world settings. Together, we aim to transform the landscape of clinical research, making it faster, more affordable, and ultimately more successful in delivering safe and effective treatments."
About Emmes Group:
Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (https://www.newmountaincapital.com). Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Emmes Group has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, rare diseases, and neuroscience. Today, the company is transforming the future of clinical research, by creating the industry’s first native digital and AI based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence.
About Miimansa AI
Miimansa AI is a health tech startup at the forefront of AI and machine learning applications in life sciences and healthcare. The company is led by former faculty and alumni from IIT Kanpur and Stanford University. Specializing in clinical data management and biomedical research, Miimansa AI develops innovative solutions that leverage large language models to automate and enhance various aspects of clinical research.
Contact Information
For media inquiries, please contact:
Dana Roche
Director of Marketing, Emmes Group
Phone: +1 202 380 5168
Email: droche@emmes.com
Priyanka Kalia
Manager, Solutions Marketing, Miimansa AI
Phone: +91 124 416 4840
Email: priyanka.kalia@miimansa.com
Press Release
ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine.
ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine.
×
Press Release
Company News
- Multiple Phase III studies are expected to be conducted across North America, Central and South America, UK and other global clinical sites.
- VaxTrials, part of Emmes Group, selected to provide comprehensive clinical research services
- Veridix AI, part of Emmes Group, will provide Advantage eClinical and other platform capabilities critical to accelerate and improve study execution
ILiAD Biotechnologies, LLC, a late-stage biotech development company dedicated to the prevention of disease caused by Bordetella pertussis, today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.
ILiAD selected Emmes Group for their expertise in vaccine development, agility in managing complex clinical trials, strong local market presence, and their integrated technology capabilities. Emmes Groups’ VaxTrials unit has previously demonstrated proficiency and clinical trial excellence through their successful support of ILiAD’s Phase II IB-201P BPZE1 study.
Dr. Keith Rubin, CEO of ILiAD Biotechnologies, commented, “Selecting Emmes Group for our Phase III BPZE1 trials has been a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ specialization in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”
"We are honored and pleased that ILiAD has selected Emmes Group as its partner to continue the clinical development of BPZE1. We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations.” said Sastry Chilukuri, Chief Executive Officer of Emmes Group.
About Pertussis
Pertussis (whooping cough) is a life-threatening disease caused by the highly contagious respiratory bacterium Bordetella pertussis. According to U.S. Centers for Disease Control and Prevention, each year pertussis affects approximately 16 million people globally, accounting for nearly 200,000 deaths. Although estimated global vaccination coverage is 84%, current vaccines have failed to control pertussis epidemics.
About BPZE1
BPZE1 is the leading next-generation pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection (colonization) and disease (whooping cough). BPZE1 is being developed to block B. pertussis from colonizing the nasal passages of adults and children, to protect adults and children from whooping cough, and to potentially prevent transmission, including transmission to infants. While ILiAD is currently focused on developing a vaccine to directly protect adults and children and to indirectly protect vulnerable infants, future development aims to immunize neonates directly. BPZE1 was developed at the Institut Pasteur de Lille (France) in the lab of Camille Locht PhD and Nathalie Mielcarek PhD.
About ILiAD Biotechnologies, LLC
ILiAD Biotechnologies (http://www.iliadbio.com) is a privately held, clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis. The company is developing and acquiring key technologies, working with leading scientists to overcome the limitations of current vaccines, investigating the impact of B. pertussis in a range of human disease, and is focused on validating its proprietary vaccines in human clinical trials.
About Emmes Group:
Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (https://www.newmountaincapital.com). The company is transforming the future of clinical research, bringing the promise of new medical discovery closer within reach for patients. Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Emmes Group has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, rare diseases, and neuroscience. Today, the company is transforming the future of clinical research, by creating the industry’s first native digital and AI based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence.
For more information, visit ILiAD Biotechnologies and Emmes Group.
Contact Information:
ILiAD Biotechnologies, LLC
Email: info@iliadbio.com
Phone: (800) 603-3525
Emmes Group
Dana Roche
Director, Marketing & Communications
droche@emmes.com
+1 202 380 5168
Press Release
Creation of the Emmes Group Will Advance Company’s 47-year Legacy and Build Clinical Research Infrastructure for the Future
Creation of the Emmes Group Will Advance Company’s 47-year Legacy and Build Clinical Research Infrastructure for the Future
×
Press Release
Company News
- New Business Unit Veridix AI Launched to Embed Technology and AI in Day-to-Day Clinical Operations
- Dr. Rama Kondru to Join the Emmes Group as CEO, Veridix AI
- Industry Leader Matthew Holt to Join Board of Directors
Emmes today announced the creation of the Emmes Group, with Sastry Chilukuri serving as its executive chairman and chief executive officer. The company also announced a new board member, Matthew Holt.
The Emmes Group will have two business units: Emmes, its Clinical Research Organization (CRO) led by Peter Ronco, and Veridix AI, the newly launched technology and artificial intelligence (AI) group, led by recently appointed executive Dr. Rama Kondru.
Chilukuri will share plans to build a technology- and AI-first clinical research infrastructure during his presentation this Thursday, January 11th at the J.P. Morgan Healthcare Conference.
“We have an opportunity to advance Emmes’ 47-year legacy of excellence in clinical research by building the clinical research infrastructure of the future,” stated Chilukuri. “Our new Veridix AI business unit will embed technology and generative AI into all aspects of clinical trials. Emmes is a full-service CRO with more than 1,600 employees, supporting clinical research in over 70 countries. We are one of the top clinical service providers to the U.S. government with industry-leading capabilities in cell and gene therapy, vaccines and infectious diseases, and ophthalmology.
“AI is now helping us learn the language of biology to rapidly generate disease insights and advance new treatments,” Chilukuri continued. “Our proprietary Clinical Generative AI platform, will help us build the clinical research infrastructure needed to bring these treatments to patients faster with high quality.”
The Emmes Group also added a new member to its board of directors, whose background adds strength to the new strategy. Matthew Holt is managing director and president, private equity, of New Mountain Capital, with a proven track record of rapidly digitizing and scaling healthcare service businesses.
About the Emmes Group
The Emmes Group is dedicated to advancing public health and biopharmaceutical innovation throughout the world. Our legacy CRO business Emmes, founded in 1977, provides clinical services tailored to meet the needs of its public and private sector partners. Our Veridix AI business is focused on delivering innovative technology solutions to create the clinical trial infrastructure of the 21st century. To learn more about how we are modernizing clinical research and having a positive impact on patients' lives, visit the Emmes Group website at www.theemmesgroup.com.